Immunohistochemical analysis of expressions of RB1, CDK4, HSP90, cPLA2G4A, and CHMP2B is helpful in distinction between myxofibrosarcoma and myxoid liposarcoma

Tao Wang, Mark A. Goodman, Richard L. McGough, Kurt R. Weiss, Uma N.M. Rao

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

The role and diagnostic efficacy of gene and protein products RB1, CDK4, CHMP2B, HSP90, and cPLA2G4A, all previously shown to be involved in tumor genesis and cell proliferation, were examined by immunohistochemical techniques in 32 cases of myxofibrosarcomas and 29 myxoid liposarcomas (all diagnosis had been confirmed by fluorescence in situ hybridization). HSP90 demonstrated strong nuclear and cytoplasmic positivity in all myxoid liposarcoma cases, while only 4 myxofibrosarcomas showed scattered HSP90 positivity. All but 4 cases of myxofibrosarcoma displayed strong positivity for cPLA2G4A, while only 2 myxoid liposarcoma cases were cPLA2G4A positive and both were CHMP2B negative. Overexpression of both cPLA2G4A and CHMP2B also suggested higher tumor grade. In conclusion, HSP90 and cPLA2G4A immunohistochemical stains are useful markers to distinguish myxofibrosarcoma from myxoid liposarcoma.

Original languageEnglish (US)
Pages (from-to)589-599
Number of pages11
JournalInternational Journal of Surgical Pathology
Volume22
Issue number7
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

Keywords

  • CDK4
  • CHMP2B
  • CPLA2G4A
  • HSP90
  • myxofibrosarcoma
  • myxoid liposarcoma
  • RB1

ASJC Scopus subject areas

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Immunohistochemical analysis of expressions of RB1, CDK4, HSP90, cPLA2G4A, and CHMP2B is helpful in distinction between myxofibrosarcoma and myxoid liposarcoma'. Together they form a unique fingerprint.

Cite this